Protein modification by ubiquitination has emerged as a critical regulatory event in virtually all aspects of cell biology. Ubiquitination is a reversible process, and ubiquitin moieties can be removed from polypeptides by deubiquitinating enzymes (DUBs). TGF-? is a cytokine with a key role in tissue homeostasis and cancer. In advanced tumours TGF-? switches from a tumour suppressor role to one as an oncogenic factor by inducing pro-invasive and pro-metastatic responses. We have recently identified a number of DUBs, which are overexpressed in glioblastoma, breast and ovarian cancers that act as potent activators of TGF-? pathway. Dr Eichhorn is interested in studying the regulation of these DUBs on the TGF-? pathway and their role in cancer progression.

Adjunct Assistant Professor, Cancer Science Institute of Singapore, NUS
Adjunct Assistant Professor, Department of Pharmacology, Yong Loo Lin School of Medicine, NUS

Year(s) Degree (if applicable) Institute
1996 B.Sc University of Western Ontario
2001 Ph.D. University of Newcastle upon Tyne
2013 – 2017 Principal Investigator, Cancer Science Institute of Singapore, NUS
2013 – 2017 Assistant Professor , Department of Pharmacology, Yong Loo Lin School of Medicine, NUS
2010 – 2012 Instructor of Medicine, Dr. Jose Baselga, Harvard Medical School
2010 – 2012 Assistant in Genetics, Dr. Jose Baselga, Massachusetts General Hospital
2006 – 2010 Postdoctoral fellow, Lab of Dr. Jose Baselga, Vall d’Hebron Institut de Oncologia
2001 – 2006 Postdoctoral fellow, Lab of Rene Bernards, Netherlands Cancer Institute